Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC–MS-MSReportar como inadecuado

Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC–MS-MS - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Rheumatology and Therapy

, Volume 2, Issue 2, pp 183–195

First Online: 10 July 2015Received: 06 February 2015


IntroductionHydroxychloroquine HCQ, 4-aminoquinoline, is an antimalarial drug and has become a basic therapy for rheumatic disease treatment.
It can stabilize the condition of SLE patients and reduce the chances of patient relapse through its immunosuppressive function and antiinflammatory effects.
This drug was absorbed completely and rapidly by oral administration, but has a prolonged half-life for elimination.
The objective of this study was to evaluate the pharmacokinetic parameters and relative bioequivalence of a new generic test formulation with the branded reference formulation of HCQ in healthy Chinese male volunteers.
This study was designed to acquire regulatory approval for the test formulation.

MethodsThis study was conducted with a randomized, single-dose, two-period, and crossover design.
The male subjects were randomly assigned to two groups at a 1:1 ratio to receive 0.2 g hydroxychloroquine sulfate tablets 0.1 g-piece of the two formulations after a 3-month washout period then administered the alternate formulation.
Study drugs were administered after overnight fasting over 10 h.
Plasma concentrations of hydroxychloroquine were measured by a validated LC-MS-MS method.
The following pharmacokinetic properties were determined by a noncompartmental pharmacokinetic method: Cmax, Tmax, AUC0–t, AUC0–∝, and t1-2.
The bioequivalence between the test and reference products was assessed based on the following parameters: Cmax, AUC0–60d, and AUC0–∝ using the ANOVA method.
If the 90% CI for AUC0–t was within 80–125% and for Cmax was within 70–143% of the statistical interval proposed by the SFDA, the two formulations were assumed bioequivalent.
Concerning the main pharmacokinetic charateristics of hydroxychloroquine, a long half-life drug, the pharmacokinetic parameters of 0–72 h were determined according to the FDA.
Furthermore, a comparison was made between the parameters at 0–60 days and 0–72 h to evaluate whether a truncated AUC method can be applied to estimate the relative bioavailability of HCQ.
Tolerability was assessed by monitoring vital signs and laboratory tests and by questioning subjects about adverse events.

ResultsThe 90% CI of Cmax for HCQ is 103.8–142.3%; the AUC0–60 is 100–114.2% and AUC0–∝ 100–115.5%.
Both met the criteria according to the SFDA’s guidelines for bioequivalence.
The relative bioavailability was 109.5% according to AUC0–60d and 110.7% according to AUC0–∝.
No serious or unexpected adverse events were observed.

ConclusionsIn this study, the pharmacokinetic studies and results were conducted so that the test and reference formulations of HCQ met the Chinese criteria for assuming bioequivalence.
Both formulations were well tolerated in the population studies.

KeywordsBioequivalence Hydroxychloroquine HCQ Pharmacokinetics  Download fulltext PDF

Autor: Hong-wei Fan - Zhi-xiang Ma - Jing Chen - Xing-ye Yang - Jun-lin Cheng - Ying-bin Li



Documentos relacionados